Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 King Starts Phase II for Pain Drug | Contract Pharma

What are you searching for?

Sign in

King Starts Phase II for Pain Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

King Pharmaceuticals has initiated the Phase II trial evaluating the efficacy and safety of T-62, an investigational drug for the treatment of neuropathic pain.

Dr. Eric Carter, chief science officer of King, remarked, “T-62, a new chemical entity, is an adenosine A1 allosteric enhancer that increases the effectiveness of the body’s endogenous adenosine to treat neuropathic pain. The successful development of this product would address a substantial unmet medical need for more effective medicines to treat this serious condition.”

The Phase II trial is a multicenter, randomized, double-blind, placebo-controlled study assessing the analgesic efficacy and safety of T-62 in subjects with postherpetic neuralgia and its associated pain. The study is expected to enroll approximately 130 patients in as many as 20 study centers and will evaluate two doses of T-62 and placebo utilizing a parallel design. Each patient will complete a seven-day screening period, a 28-day treatment period, and a 14-day post-treatment period.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters